Clinical trials: Small Cell and Non-small Cell Lung Cancer
Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors.
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
- Trial name
- NCT07557225
- Testing
- 18F-T2 PET/CT
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC
ALK TKIs, particularly second- and third-generation ALK TKIs, have significantly improved progression-free survival (PFS) in patients with advanced ALK-positive non-small cell lung cancer (NSCLC).
- Trial name
- NCT07671560
- Testing
- Combined group of ensatinib and arotinib
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Qiming Wang
Non-small Cell Lung Cancer
Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer
This study was designed to explore the efficacy and safety of Crizotinib as a first-line treatment for advanced NSCLC with ROS1 rearrangement positive mutation in the real world, explore the new drug resistance mechanism of ROS1…
- Trial name
- NCT03646994
- Testing
- Crizotinib
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer, Chronic Obstructive Pulmonary Disease
Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)
Bone-marrow-derived progenitor cells (EPCS) play an important role in neovascularization and tumor growth. In lung cancer, angiogenesis is an important event in mechanisms of tumor proliferation and metastasis.
- Trial name
- CBNPC:PCE (NCT00826683)
- Testing
- Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Non-small Cell Lung Cancer, Non-small Cell Carcinoma
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
This study will explore the best dose of radiation to be used when treating stage I-III non-small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) or hypo-fractionated radiotherapy (HypoFrx-RT) that is…
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II
- Trial name
- NCT05451173
- Testing
- Stereotactic body radiotherapy, Hypofractionated radiotherapy, Durvalumab
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Alexander Chi
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China
This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg/5 µCi dose of…
- Trial name
- NCT07620951
- Testing
- [14C]Zorifertinib Oral Formulation
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Advanced Non-small Cell Lung Cancer, EGFR Mutation
A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants
Researchers are looking for a better way to treat men who have advanced non-small cell lung cancer (NSCLC). NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body.
- Conditions
- Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
- Trial name
- NCT06221475
- Testing
- BAY2927088 coated tablet 10 mg, [14C]-BAY2927088 solution for infusion, [14C]-BAY2927088 oral solution
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bayer
Lung Cancer, Nonsmall Cell, COPD
Breathe Easier II: A Dyad-based Multiple Behavior Intervention
This pilot randomized control trial (RCT) will test a 12-week, multiple behavior intervention physical activity and stress management for survivors with early stage lung cancer (stages I-III) and their family members (1 survivor…
- Conditions
- Lung Cancer, Nonsmall Cell, COPD, Self-Management, Physical Inactivity
- Trial name
- BE (NCT05956782)
- Testing
- Breathe Easier
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Stage III, Non-small Cell Lung Cancer
Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer
This is a prospective, one-arm, phase II study aimed at evaluating tislelizumab combined with platinum-containing dual-drug chemotherapy as a neoadjuvant treatment, supplemented with tislelizumab after surgery in patients with…
- Trial name
- NCT04865705
- Testing
- tislelizumab
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Non-small Cell Lung Cancer
FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC
This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with standard first-line therapy to enhance the anti-tumor immune effect at the same time, thereby extending the…
- Trial name
- NCT06403111
- Testing
- Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Changzhou No.2 People's Hospital
Non-small Cell Lung Cancer, Bone Metastases
Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates
A multicenter Prospective Study to assess the screening methods, parameter of NTX and the efficacy and safety of zoledronic acid treatment in addition to anti-tumor therapy in patients of non-small cell cancer with bone…
- Trial name
- BLEST (NCT00765687)
- Testing
- bisphosphates
- Where
- China
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer, Neoadjuvant Therapy
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer, Neoadjuvant Therapy, Radiotherapy, Immunotherapy
- Trial name
- NCT06065813
- Testing
- Toripalimab, Conventional segmental radiotherapy, opreation
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Northern Jiangsu People's Hospital
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
- Conditions
- Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
- Trial name
- RAD301 (NCT05799274)
- Testing
- RAD301 ([68Ga]-RAD301)
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Radiopharm Theranostics, Ltd
Lung Cancer, Non-small Cell Lung Cancer Stage I
Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer
The goal of this prospective, case-control study is to discover the specific "omics" biomarkers of early stage of lung cancer using the non-invasive samples (breath, urine and serum) in a total of 200 subjects (100 healthy…
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Lung Cancer Diagnosis
- Trial name
- NCT06341387
- Testing
- Breath, urine and blood analysis
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
Non-small Cell Lung Cancer
Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
This is a double-blind, randomized controlled study evaluating the efficacy and safety of HGXJT in combination with ICI-based standard treatment in lung cancer patients with bone metastases.
- Trial name
- NCT05378334
- Testing
- ICI, Chemotherapy, Bone-protecting and Mass-dispersesing Decoction
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Non Small Cell Lung Cancer
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
- Trial name
- TRUST-II (NCT04919811)
- Testing
- Taletrectinib
- Where
- 77 sites in United States, Canada and 7 more
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
Non Small Cell Lung Cancer, Influenza Vaccine
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.
- Trial name
- NCT04355806
- Testing
- PD-1/PD-L1 inhibitors, Inactivated trivalent influenza vaccine
- Where
- 2 sites in China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-small Cell Lung Cancer
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
This study was to explore the efficacy of ALK-TKI in lung squamous cell carcinoma. Approximately 5% of lung adenocarcinomas have oncogenic fusions of EML-4 and ALK a mutation associated with tumorigenesis and migration.
- Trial name
- ATPase (NCT05014464)
- Testing
- Crizotinib
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Hunan Province Tumor Hospital